Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ipsen, Invida Group Sign Agreement To Commercialize Drugs In South-East Asia

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI- The French firm Ipsen and Singapore's Invida have forged an exclusive distribution and promotion deal covering a number of Ipsen's oncology and endocrinology drugs in select South-East Asian countries. The agreement is expected to help expand the geographical reach of Ipsen's specialty-care portfolio in the Asia Pacific region

You may also be interested in...



Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products

SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners

Invida Charts 25% Growth Plan, Banking On Selective Partnerships For High-value Products

SINGAPORE - Big Pharma's slow shift from primary care products to specialty care products like the oncology segment has helped Invida develop robust commercial relationships with multiple partners

Older Primary Care Drugs Matter – For Cash, And For Emerging Market Access

Europe's mid-sized pharma may be going specialist like much of the rest of the industry, including some of the biggest companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel